After Amgen (AMGN) announced topline data from its Phase 2 study of MariTide, the company’s subcutaneously administered GLP-1 weight loss drug, ...

Stocks were higher Tuesday afternoon as investors digested earnings reports from several retailers and awaited results from ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose an average of up to 20 percent of th ...

STORY: Shares of Amgen on Tuesday were on track for their biggest percentage fall in more than two decades after the ...

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...

MariTide was administered monthly or less frequently, which could provide an edge over the popular weekly injections ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

Amgen stock was dropping sharply Tuesday after releasing what looked like positive data from a Phase 2 study for its ...

The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...